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Background: Previous studies have found a link between a low DNA repair capacity (DRC) level and increased
cancer risk. Our aim was to assess the statistical association of DRC level and breast cancer (BC) using a case–
control epidemiological study in a Hispanic community.
Methods: We conducted a comparative observational study to assess the validity of DRC in detecting BC in 824
women throughout Puerto Rico. Over a 6-year period, we compared 285 women newly diagnosed with BC to 539
without BC. DRC levels were measured in lymphocytes by means of a host-cell reactivation assay. We assessed the
sensitivity, specificity, and association using the receiver operating characteristic curve analysis. Multiple logistic
regression-adjusted odds ratios were estimated with 95% confidence level to measure the strength of the
association of DRC and BC after adjusting for all confounders simultaneously.
Results: Compared to women without cancer, women with BC showed an average decrease of 60% in their DRC
levels (p < 0.001). Validity of the association of DRC as a measure of BC risk showed a sensitivity of 83.2% and
specificity of 77.6% (p < 0.0001).
Conclusions: Our results support the usefulness of DRC level as a measure of BC risk. Additional studies in other
populations are needed to further verify its usefulness.
Keywords: Breast cancer, DNA repair capacity, Association, Risk, BiomarkerBackground
Breast cancer (BC) is the most common cancer world-
wide affecting women, accounting for 20% of all malig-
nancies in females [1]. In 2010, an estimated 207,090 U.
S. women were diagnosed with BC [2]. In Puerto Rico,
BC accounted for 30% of all cancers in 2009. This
percentage represented 1,776 new patients, which was
the highest incidence per organ (Cancer Registry of
Puerto Rico). Despite the declining trend in mortality,
BC is currently the second leading cause of cancer death
in women living in the U.S. and the first cause of cancer
mortality in Puerto Rican women [3]. Even with the* Correspondence: jmatta@psm.edu
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reproduction in any medium, provided the ormany advances made in diagnostic procedures and treat-
ments for BC, early-detection methods are needed.
Because age is a principal risk factor for cancer, studies
on aging have provided additional understanding of
DNA repair processes [4]. However, aging is not the only
cause of genomic instability that can lead to cancer.
Individuals vary in their inherent sensitivities to muta-
gens and carcinogens due to differences in their DNA
repair capacity (DRC) levels [5]. Several studies have
shown that lower DNA repair capacity correlates with
higher cancer risk [6-18]. Epidemiological studies using
functional repair assays in lymphocytes have also
demonstrated that DRC varies greatly among individuals,
and that a low DRC is a significant risk factor for the
development of several types of cancer [9,12,14,17,19-21].
With respect to DNA repair in cases of BC, the
Nucleotide Excision Repair (NER) pathway is receivingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phocytes have demonstrated an association between BC
incidence and NER deficiency [11,23-28]. Collectively,
they suggest that NER deficiency may contribute to the
etiology of sporadic and familial BCs. If we can learn
more about that association and develop a readily available
clinical method for detecting DRC, then we can identify,
treat, and arrest BCs earlier.
The aim of our study was to to assess the statistical
association of DRC level and breast cancer (BC) using a
case–control epidemiological study in a Hispanic
community. In contrast to previously published studies,
including our (Ramos et al. 2004), we used a large sample
size (824 participants) for increased statistical power. This
clinic-based, observational study [29] compared recently
diagnosed, treatment-naïve, histopathologically confirmed
BC patients to women without BC.
Methods
Epidemiologic design
Over a 6-year period, we recruited 824 women of
Hispanic origin, age 21 or older: 285 women newly
diagnosed with BC and 539 without BC. Calculations of
sample size done initially revealed that a sample size of
824 participants (312 women with BC, 515 women with-
out BC) would allow us to have a statistically significant
odds ratio as low as 1.7 when the percent exposed to a
low DRC among controls is 15% or higher (e.g., 15%
controls are 21 to 30 years of age) with 5% significant
level and 80% of statistical power.
The population represents a genetically diverse popula-
tion that is an admixture of European, African, and
Amerindian ethnic groups (per studies from 106 ancestry
markers—Dr. Julie Dutil, unpublished observations).
Women who were obtaining mammograms and other
routine gynecological and primary care/screening services
at the same medical offices where patients with BC were
being treated were recruited consecutively at the following
locations: Ponce School of Medicine and Health Sciences
Outpatient Clinic, Auxilio Mutuo Hospital (San Juan),
Damas Hospital (Ponce), and St. Luke’s Hospital (Ponce),
as well as Yauco and other selected collaborating cities
throughout Puerto Rico, representing 65 (83%) of the 78
municipalities (counties) on the island. Because Puerto Rico
offers universal health insurance coverage, any healthy
women who might develop BC would be treated in the
same facilities where BC patients were recruited. This selec-
tion procedure minimized selection bias due that could
have otherwise been a factor (site, screening/treatment
modalities) if healthy women were recruited from the
general population by other means (e.g., through random-
digit dialing, as noted by Rothman et al. [30]).
This study was approved by the IRB of the Ponce
School of Medicine and Health Sciences (Ponce, PuertoRico) and participating hospitals. Informed consent was
obtained from all participants before interviewing them,
drawing blood samples, collecting tumor material, and
obtaining pathology reports.
The two main inclusion criteria for selecting women
without BC were 1) a normal breast examination done by
a primary care physician and 2) a normal mammogram,
both within the last six months. These criteria reduced the
likelihood of the existence of undiagnosed BC in this
cohort.
We studied only recently diagnosed, treatment-naïve
BC patients with primary tumors. Exclusion criteria
included those with metastatic BC, secondary BC, breast
metastases from another type of cancer, or any acquired
or genetic immunodeficiency. Because blood transfu-
sions, chemotherapy, and radiotherapy can significantly
affect DRC [31-33], patients who had received any of
those treatments in the past 5 years were also excluded
from the study.
Pathology reports from all patients were obtained to
confirm the 1) diagnosis, 2) tumor grade, 3) tumor size, 4)
presence or absence of axillary lymph node metastasis,
and 5) other clinically relevant information. An epidemio-
logical questionnaire soliciting information and variables
related to BC risk was provided to each participant.
Blood collection and isolation of lymphocytes from women
Approximately 30 mL of peripheral blood was obtained
from each participant and stored in heparinized tubes.
The lymphocytes were then isolated by the Ficoll gradient
technique and suspended in 2 mL of freezing media con-
taining 10% dimethyl sulfoxide, 40% RPMI 1640 medium,
50% fetal bovine serum, and 1% antibiotic/antimycotic.
Aliquots were stored in a −80°C freezer for 1–3 weeks.
The lymphocytes were later thawed in batches of 5–7
samples for the host-cell reactivation (HCR) assays (details
follow). Collection periods were approximately the same
for patients and women without BC because recruitment
was conducted concurrently.
Plasmid preparation for host cell reactivation (HCR) assay
for measuring DNA repair capacity
The late Dr. Lawrence Grossman (Johns Hopkins School
of Public Health, Baltimore, MD) provided the luciferase
plasmid for the HCR assay and the protocol for its use.
A non-replicating plasmid expression vector (pCMVluc)
of 4,863 base pairs was genetically engineered to contain
a bacterial luciferase reporter gene that is not present in
a mammalian cell. The gene was damaged by ultraviolet C
radiation (254 nm) exposure in a controlled, quantitative
manner (dose–response curve) so that the level of its
expression was a direct measure of the repair capacity of
the host mammalian cell. The plasmid construct containing
the luciferase gene (LUC) was irradiated at 0, 350, and 700
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construct and its validation have been described previously
[34]. The controlled, quantitative UV exposure produced a
dose–response curve so that the level of its expression was
a direct measure of the repair capacity of the host mamma-
lian cell.
HCR assay to measure DRC
The HCR assay that we utilized to measure DRC levels in
lymphocytes has been described in previously published
molecular epidemiological studies of cancer [9,11,12,34-37].
This assay measures the total DRC of transfected lympho-
cytes. Results reflect the host cells’ overall repair capacity,
although HCR primarily detects activity of the nucleotide
excision repair (NER) pathway [38].
To assess this assay’s precision, we used a data subset
that involved duplicates of 50 women with BC, 50
women without BC, and 90 samples of three commercial
cell lines. A correlation of 0.97 (95% overall confidence
interval: 0.95–1.00) was found (P < 0.001; data not
shown). In addition, we repeated the assay if we found
any inconsistencies between duplicates.
The measurement of DRC has a coefficient of variation
of 23% in the data presented in this study. A batch effect
associated with inter-technician variability in performance
of the DRC assay was found; this was corrected by exclud-
ing 36 samples (35 BC cases, 1 control). Grossman and
Wei [5] demonstrated that, at this precision, our assay can
distinguish both intra- and inter-assay variation by being
able to maintain the ranks of DRC values in samples
measured in triplicate from multiple patients.
Validation of stable transfection
To confirm achievement of stable transfection, we utilized
the Dual-GloRW Luciferase Assay System (Promega;
Madison, WI), which is based on the combined use of the
Firefly and Renilla luciferases proteins as co-reporters. The
assay allows for analysis of mammalian cells (e.g., lympho-
cytes) containing genes for Firefly and Renilla luciferases
grown as positive controls. To determine whether our
results would vary significantly between cryopreserved
versus fresh blood samples, we took dual samples from 5
patients (total of 10 blood samples) and assayed 5 immedi-
ately after phlebotomy (fresh), then cryopreserved the other
5 samples at −80°C and analyzed those several weeks later.
Preparation of samples and controls
Previously frozen peripheral blood lymphocytes from
patients and women without BC were assayed in
batches, as described by Ramos et al. [11]. Peripheral
blood lymphocytes with >95% viability were incubated
for 72 h with phytohemagglutinin and then were
transfected with undamaged or damaged plasmid DNA.
Cells isolated from xeroderma pigmentosum patientscorresponding to complementation groups C and D
(XPC, XPD) were used as positive controls (cell lines
GM 02246D and GM 02253F, respectively; Coriel Institute
Medical Research; Camden, NJ).
Calculation of DRC
The assay for the gene expression of luciferase activity
was measured using a luminometer (Turner Designs,
model TD-20/20, Sunnyvale, CA). The percentage of
DRC was calculated as the percentage of luciferase activity
present after the repair of damaged plasmid DNA,
compared to the DRC of undamaged plasmid DNA
(100%). This method produced a range of DRC values
from nearly 0 to 19% DRC.
Statistical analyses
The association of DRC levels was based on the accuracy
detecting BC when a woman has a high versus low DRC
level. Data analyses were conducted by using the IBM
SPSS statistical package version 17.0 (IBM; Armonk, N.Y.).
The Wilcoxon or Mann Whitney U-test for independent
samples was used to assess the statistical significance of the
mean difference to account for non-normally distributed
variables such as in DRC [39].
During crude analysis, variables such as DRC, age,
weight, and body mass index, were first analyzed as
continuous variables. The mean difference was used to
assess DRC and anthropometric difference between
patients with BC and women without BC using the
logistic regression model [39]. After this step, for stratified
analysis, continuous variables were categorized by using
percentiles as cutoff points [29]. DRC was divided in low
and high DRC using the median from the whole sample,
also to divide on low, medium and high DRC, terciles were
used from the whole data. Stratified analyses were
conducted to identify and assess potential confounders or
interaction effects of the association between BC and DRC
[29,30]. After stratified analyses, a multivariable logistic
regression model was used, odds ratio was estimated with
95% confidence level to assess the strength of the associ-
ation between DRC level and BC adjusting for potential
confounders [30].
Results
Association between DNA Repair capacity levels and
population variables in women with and without breast
cancer
Women with BC (n = 285) had a mean DRC of 2.40%; this
was 60% lower than the average DRC level (P < 0.001,
Mann Whitney U-test) than in the 539 women without
BC, they had a mean DRC level of 6.13% (Figure 1). For
every 1% decrease in DRC, there was 64% greater likelihood
of having BC. These findings were statistically significant
(p<0.05). ROC curve analysis [40,41] was used to assess the
Figure 1 % DRC of female cohorts in Puerto Rico with breast cancer (n = 385) and without breast cancer (n = 539). DRC was measured
in lymphocytes by a host reactivation assay with a luciferase reporter gene. Women with breast cancer have a DRC that, on average, is 60% lower
than women without breast cancer (P < 0.001, Mann Whitney U-test).
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the ROC curve was found to be 88.4% (95% CI: 86%,
90.9%), and the 3.7% DRC cutoff point reached 83.2% sensi-
tivity and 77.6% specificity (Figure 2).
Table 1 presents the crude and multivariate adjusted
odds ratios to determine the strength of the associations
between BC and other selected variables. Different
blocks of variables were tested to find the best model for
adjusting for potential confounding. The model that was
finally used included, age, body-mass index, marital
status, number of children, family history of BC, and
smoking. The odds of having BC increased 2% with
every year of age (95% CI: 1.01, 1.05). A family history of
BC increased the odds of having BC by 1.7 times (95%
CI: 1.0, 2.8). Interesting but statistically not significant
findings included the following: the odds of having BC
increased 10% with the birth of each child, 3% by each
percent increase in BMI, 40% by history of pregnancy
and 10% by smoking, also, for breastfeeding or alcohol
intake; those decreased the odds for BC by 20%, respect-
ively. Compared to married women, widows had 4.6
times higher odds of having BC (95% CI:1.6, 13.7); singlewomen had 5.9 times higher odds of having BC (95% CI:
2.3, 15.6), and divorced had 3.6 times more likelihood of
having BC (95% CI: 1.2, 10.5).
Table 2 presents the crude and multivariate adjusted
associations between BC and DRC. When DRC was
analyzed as a continuous variable the adjusted odds ratio
was 2.3 (95% CI: 2.0, 2.6) (P < 0.001). The associations
between BC and DRC, both as a continuous and as a
categorical variable, became stronger after multivariate
adjustment (P < 0.001). The DRC in three categories
levels showed a strong association with BC and a
statistically significant linear trend (P < 0.001). Women
with low DRC levels (≤ 3.0%) had 60.6 (95% CI: 32.0,
114.6) times the odds of having BC as women with high
DRC levels (≥ 5.81%) when adjusting for potential
confounders.
Discussion
While the HCR assay as described in this study assesses
the overall DNA repair capacity, it preferentially
measures repairs made by the nucleotide excision repair
(NER) pathway. NER repairs bulky adducts caused by
Figure 2 DRC detecting the presence of breast cancer ROC
Curve (285 cases and 539 Controls).
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ones contributing to carcinogenesis presented by BC
patients [5-8]. Low levels of NER repair have been
detected in peripheral blood lymphocytes and tumor
samples of BC patients [5-8]. In addition, exposure to
ionizing radiation is a risk factor for BC [9]. DNA lesions
arising from ionizing radiation and many carcinogens
causing bulky lesions are repaired by NER and deficiencies
in the NER pathway can increase genomic instability.
The HCR assay, developed in the early 1990s, provided
a way to obtain a quantitative, phenotypic measurement of
DRC in lymphocytes [5]. The subsequent development of a
plasmid based on luciferase activity instead of radioactivity
resulted in stable transfection efficiencies [38]. Because of
the high cost of this assay, its technical complexity, and its
labor intensiveness, relatively few laboratories in the world
currently utilize it for large-scale molecular epidemiology
studies of cancer [9,11,14,15,17,36,37,43].
Studies published to date of HCR assays of lympho-
cytes have frequently, but not always [34], found a link
between a low DRC and increased cancer risk. Our
group [11] was the first to report that a low DRC was a
risk indicator for BC. That initial DRC study consisted
of a small sample size (n = 36 patients) and did not have
the benefit of ROC analysis or a well-defined percent
DRC level (e.g. low, medium, high) as a BC risk estima-
tor compared to the analyses presented in this study. Inthe current study, we furthered classified DRC into
terciles; low, medium and high levels. This methodology
has the potential to serve as a biomarker of risk of BC
(United States Patent Trade Office US 8,163,473 B2).
Our adjusted OR (2.3) for DRC as a continuous variable is
within the range of similar ORs values for published studies
for basal cell carcinoma skin cancer (Wei et al. 1993), lung
cancer (Wei et al. 2000), head and neck cancer (Cheng
et al. 1998), prostate cancer (Hu et al. 2004) and BC
(Shi et al. 2004) [12,26,44,45].
However, when DRC was analyzed either as a dichot-
omous or as a categorical variable (low, medium, high),
the ORs are much higher. Such high ORs are unusual
and have been reported only a few studies. For example,
Latimer et al. (2010) recently estimated that the sensitiv-
ity of detecting tumors based on reduced NER levels
alone is 95%, the specificity is 74%, and the odds ratio is
53.8 (95% CI, 28.3–102.4). This group demonstrated the
critical importance of the NER pathway in BC by meas-
uring the NER capacity in breast tumors (n=19) and
normal primary cultures expressed relative to the mean
of these normal BC tissues. The mean NER capacity of
the tumor samples was significantly lower than that of
normal breast tissues, averaging only 44% of normal
activity (P < 0.001). Some other studies have also
reported very high ORs when strong associations are
found. This has occurred with the association of cervical
cancer with HPV exposure. Some HPV studies have
reported very powerful associations. For example, a case
control study for HPV by Powell et al. (2011) reported
ORs as high as 2770; Chen et al. (2011), as high as 75;
Chuang et al. (2012), ORs 18.1 and higher; and Almonte
et al. (2011), ORs of 16.1 [46-49].
In this study, we observed an unusually strong increment
on the OR after adjustment. Therefore, we repeated the
analysis entering, first entering DRC alone in the model;
then the covariates were entered one by one. In doing that,
we found that the adjusted OR increased gradually as we
added each covariate to the model.
No evidence of interaction terms were found in the
multivariate logistic model (p>0.05), so DRC can be
considered as a potential independent risk factor for
DRC because it is biologically plausible, shows a strong
association, and exhibits a dose–response relationship
after adjusting for all confounders simultaneously.
Despite the usefulness of the HCR assay to estimate
DRC and detect BC risk, future prospective studies are
needed to further validate the use of this approach.
Specifically, further studies are needed to ascertain 1)
whether women without BC with a low DRC have a
higher incidence of BC compared to those who have a
high DRC and 2) whether women with BC and a low
DRC are at an increased risk of recurrent BC compared
to those with high DRC.
Table 1 Odds ratio estimation to assess the association between breast cancer (BC) and DNA repair capacity (DRC) and





Crude OR1 Adjusted OR2 P
value(95% CI) (95% CI)
Age (continuous)* 285 (56.7) 539 (52.4) 1.02 (1.02,1.04) 1.02 (1.01, 1.05) 0.001
Number of children 273(2.4) 517 (2.1) 1.2 (1.1, 1.3) 1.1 (1.0, 1.3) 0.055
# Missing (34)
Increasing BMI (continuous)* 284 (27.8) 534 (27.2) 1.02 (0.9, 1.1) 1.03 (1.0, 1.1) 0.118
# Missing (6)
Family history of BC
Yes 64 78 1.7 (1.2, 2.5) 1.7 (1.0, 2.8) 0.054
No 221 461
Marital status
Married 154 362 Referent Referent
Single 61 92 4.2 (2.2, 7.8) 5.9 (2.3, 15.6) <0.001
Divorced 40 66 2.7 (1.4, 5.3) 3.6 (1.2, 10.5) 0.025
Widow 30 17 2.9 (1.4, 5.9) 4.6 (1.6, 13.7) 0.006
# Missing (2)
Irregular menstrual cycles




Yes 220 401 1.2 (0.8,1.6) 1.4 (0.8,2.2) 0.382
No 65 138
History of breastfeeding




Yes 42 98 0.8 (0.6, 1.2) 0.8 (0.5, 1.7) 0.526
No 243 441
Smoking
Yes 37 48 1.6 (0.9, 2.4) 1.1 (0.6, 2.1) 0.707
No 248 491
*Mean values presented in parenthesis.
Comparisons were measured with the crude1 and the adjusted2 multiple logistic regression odds ratio (OR)3 in the total sample divided by patients and women
without breast cancer.
1Crude or unadjusted analysis: The analysis is carried out without taking into consideration potential confounders.
2Adjusted analysis: The analysis is carried out adjusting for the potential effect of all confounding variables simultaneously by using logistic regression model. The
associations were adjusted by DRC, age, body mass index, family history of breast cancer, number of children, marital status, and/or smoking.
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BC was diagnosed; thus, reverse causation could be
present if BC lowers DRC, which would explain why we
found a low DRC associated with BC. Nevertheless,
reverse causation is an unlikely explanation of our findings
because experimental evidence demonstrates that a low
DRC or impairments in DNA repair pathways and/or
genes is a mechanistic component involved in BCcarcinogenesis [2,11,28,50,51] or relapse [24] for the
transition to hormone independence [52].
Given that newly diagnosed patients are not always
truly incident patients, we compared DRC results to
tumor size (data not shown) as a surrogate for the length
of time period between disease onset and diagnosis to
address the potential changes that DRC in lymphocytes
might have had after a woman develops BC. With these
Table 2 DNA Repair Capacity (DRC) of women with breast cancer (BC) and women without BC by age group
Variable Women with
BC n (mean DRC)
Women without
BC n (mean DRC)
Crude OR1 Adjusted OR2 P
value(95% CI) (95% CI)
Decreasing DRC (continuous)* 285 (2.41) 539 (6.13) 2.2 (1.9, 2.4) 2.3 (2.0, 2.6) < 0.001
DRC
Low (< 4.3%) 246 168 13.9 (9.4, 20.4) 15.1 (10.0, 22.9) < 0.001
High (≥ 4.3%) 39 371
DRC levels3
Low (0.0-3.0%) 213 66 54.6 (30.3, 98.5) 60.6 (32.1, 114.6) < 0.001
Medium (3.01-5.8%) 57 219 4.4 (2.4, 8.0) 13.0 (8.5, 20.0) < 0.001
High (≥5.81%) 15 254 Referent Referent
*Mean values presented in parenthesis.
Comparisons were measured with the crude1 and the adjusted2 multiple logistic regression odds ratio (OR) in the total sample divided by patients and women
without breast cancer.
1Crude or unadjusted analysis: The analysis is carried out without taking into consideration potential confounders.
2Adjusted analysis: The analysis is carried out adjusting for the potential effect of all confounding variables simultaneously by using logistic regression model.
3Chi-Square for linear trend = 233.6, p< 0.001.
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level differences by tumor size that could interfere with
our comparisons.
DRC at its cutoff point selected based on its median value
(4.3%) was found in this study to have 83.2% sensitivity and
77.6% specificity for detecting BC. ROC analysis showed a
high accuracy detecting BC (88.4% of the area under the
curve), which was statistically significant. Because any given
specific value of DRC level is associated with a quantitative
BC risk estimate, DRC has the potential to be a biomarker
to rule out BC risk in low-prevalence or low-risk popula-
tions or confirm its presence in high-prevalence or high-
risk populations. However, a higher specificity and sensitiv-
ity would increase the value of DRC as a detector of BC. In
addition, these findings need to be validated in other popu-
lations and with future prospective studies.Conclusions
Our findings confirm the hypothesis that a low DRC is
an important risk factor for BC. Thus, measuring DRC
could be a useful tool to assess BC risk, especially in
women from low-prevalence or low-risk populations,
such as the population that we studied. For every
percent unit of decrease in DRC, there is 64% more
likelihood of having BC. Although our results support
the validity of using DRC level to estimate BC risk, further
studies (including prospective studies) are needed to verify
whether such an appraisal would be a useful addition to
existing screening and risk-assessment tests for BC, as
other covariates (for example, family history, age at first
pregnancy) could modify its predictive value.Abbreviations
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